Fr. 124.00

Medication-Related Osteonecrosis of the Jaws - Bisphosphonates, Denosumab, and New Agents

Inglese · Tascabile

Spedizione di solito entro 6 a 7 settimane

Descrizione

Ulteriori informazioni

Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs
This textbook provides detailed, up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require extractions, implant insertions, and other dento-alveolar surgeries. This book will be of major interest for medical and dental students, dentists, and oral and maxillofacial surgeons as well as osteologists and oncologists.

Sommario

Pharmacology of Antiresorptive Drugs.- The Role of Antiresorptive Drugs in the Treatment of Osteoporosis.- The Role of Antiresorptive Drugs in the Treatment of Skeletal Manifestations of Malignant Diseases.- Clinical Features, Localization, Definition and Staging of the Disease.- Radiological Findings / Imaging.- General Characteristics and Risk Factors for BRONJ.- Epidemiology.- Histopathology of BRONJ.- Prevention of Osteonecrosis and Dentoalveolar Surgery Under Treatment With Antiresorptive Drugs.- Bisphosphonates and Dental Implants.- Treatment of BRONJ.- Local and Microvascular Flaps in ONJ-Treatment.- Rehabilitation of Patients After BRONJ.- Adjuvant Treatment Strategies.- Microbiology and Antibiotics.- Animal Models of ONJ.- ONJ Under Denosumab and Other New Drugs.- Possible Use of Antiresorptive Drugs in OMS.- Dental Treatment Under BPs and After BRONJ.- Dental Rehabilitation Under Bisphosphonates and After BRONJ.- History of ONJ.

Info autore

Sven Otto, MD, DDS, is a board-certified specialist in oral and maxillofacial surgery from Germany. He received both his dental degree (2002) and his medical degree (2006) from the University of Leipzig, Germany. Since 2006 he has been a resident at the Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians University of Munich, Germany. One of his major fields of interest is bisphosphonate-related osteonecrosis of the jaw, especially the underlying pathophysiology. He has published numerous articles in leading scientific journals and has lectured nationally and internationally on this subject. In 2011, he was appointed group leader for “Jaw bone and osteonecrosis of the jaw” in the Laboratory for Experimental Surgery and Regenerative Medicine (ExperiMed) of the Ludwig-Maximilians University of Munich.

Riassunto

Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs This textbook provides detailed, up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require extractions, implant insertions, and other dento-alveolar surgeries. This book will be of major interest for medical and dental students, dentists, and oral and maxillofacial surgeons as well as osteologists and oncologists.

Testo aggiuntivo

“… eine ideale Grundlage für jeden Zahnarzt und Oralchirurgen, um sich über das Krankheitsbild der Kiefernekrose unter antiresorptiven Medikamenten wie Bisphosphonaten und Denosumab zu informieren und sein Wissen bezüglich der zahnärztlichen Behandlung dieser Patienten zu erweitern. ... übersichtlich strukturierte und sehr gut illustrierte Kapitel ... in englischer Sprache erschienen, jedoch auch für Nicht-Muttersprachler sehr verständlich ... Insgesamt kann dieses Buch zahnärztlichen, oralchirurgischen und mund-, kiefer- und gesichtschirurgischen Kollegen nur empfohlen werden.” (Dr. Kleopatra Ziata, in: Bayerisches Zahnärzteblatt BZB, März 2015)

Relazione

"... eine ideale Grundlage für jeden Zahnarzt und Oralchirurgen, um sich über das Krankheitsbild der Kiefernekrose unter antiresorptiven Medikamenten wie Bisphosphonaten und Denosumab zu informieren und sein Wissen bezüglich der zahnärztlichen Behandlung dieser Patienten zu erweitern. ... übersichtlich strukturierte und sehr gut illustrierte Kapitel ... in englischer Sprache erschienen, jedoch auch für Nicht-Muttersprachler sehr verständlich ... Insgesamt kann dieses Buch zahnärztlichen, oralchirurgischen und mund-, kiefer- und gesichtschirurgischen Kollegen nur empfohlen werden." (Dr. Kleopatra Ziata, in: Bayerisches Zahnärzteblatt BZB, März 2015)

Dettagli sul prodotto

Con la collaborazione di Sve Otto (Editore), Sven Otto (Editore)
Editore Springer, Berlin
 
Lingue Inglese
Formato Tascabile
Pubblicazione 01.01.2016
 
EAN 9783662524336
ISBN 978-3-662-52433-6
Pagine 220
Dimensioni 179 mm x 254 mm x 9 mm
Peso 490 g
Illustrazioni VIII, 220 p. 83 illus., 63 illus. in color.
Categorie Scienze naturali, medicina, informatica, tecnica > Medicina > Branche cliniche

B, Medicine, ZAHNHEILKUNDE, dentistry, Oral surgery, maxillofacial surgery, ORAL AND MAXILLOFACIAL SURGERY

Recensioni dei clienti

Per questo articolo non c'è ancora nessuna recensione. Scrivi la prima recensione e aiuta gli altri utenti a scegliere.

Scrivi una recensione

Top o flop? Scrivi la tua recensione.

Per i messaggi a CeDe.ch si prega di utilizzare il modulo di contatto.

I campi contrassegnati da * sono obbligatori.

Inviando questo modulo si accetta la nostra dichiarazione protezione dati.